工作单位: European Cooperative Group for Blood and Marrow Transplantation
职务/职称: 教授
个人简介: 法国骨髓移植协会(创始成员),国际实验血液学学会(副主席:1998-1999;主席:2000-2001),EBMT(欧洲血液和骨髓移植协作组)巴黎办事处 主任,法国国家健康和医学研究院938研究所与法国核辐射安全防护研究所合作。
Professor Gorin is known for his works on stem cell cryopreservation , for developping autologous stem cell transplantation (ASCT) in dogs and for doing the first autologous stem cell tranplantation in the world, in 1976, at that time in a patient with acute myeloid leukemia. He later developped the use of ASCT for lymphomas and myelomas. His most recent research has concerned with the French IRSN (institute for radiation and nuclear safety) Mesenchymal Stromal Cells (MSC) and their use in radiation victims.
Professor Norbert-Claude Gorin has been deeply involved with the European Cooperative Group for Blood and Marrow Transplantation (EBMT). He has been the secretary and then the chair of the historical working party on autologous stem cell transplantation (ASCT) and later the chair for 8 years of the Acute Leukemia working party. He has organized several meetings including the 1997 (Aix les Bains France) and 2011 (Paris, palais des congres) EBMT annual meetings and the 1989 and 2003 meetings of the International Society for Experimental Hematology (ISEH). He has been the president of ISEH in 2000-2001. Pr Gorin has developped in Paris at hopital Saint Antoine the Paris office of the EBMT which is heavily involved with the analysis of scientific data of the EBMT registry (more than 480000 transplants). He is the Scientific chair of the Boxiao Foundation (Fondation de France) whose aim is to promote scientific collaboration between France and China in the field of hematology and cell therapy.
讲座视频:0
论文摘要:2
461
0
0
日期 | 时间 | 会场 | Session | 角色 | 讲题 |
---|---|---|---|---|---|
2021-06-18 | 14:00-14:30 | 三层董事会会议室 |
CSH-EBMT dialogue session1 |
主持 | |
2021-06-18 | 15:00-15:30 | 三层董事会会议室 |
CSH-EBMT dialogue session3 |
主持 | |
2021-06-18 | 15:55-16:15 | 窑湾厅 |
青年成长分会场9 |
讲者 | AUTOLOGOUS STEM CELL TRANSPLANTATION AS A MODEL FOR OPTIMIZING PRE AND POST HSCT TREATMENT FOR AML |